Glycomet-GP 3 Tablet (Metformin/Glimepiride)

Product Overview

Glycomet-GP 3 Tablet is a prescription oral antihyperglycemic agent indicated for the management of Type 2 diabetes mellitus. It combines two well-established pharmacologic agents, metformin and glimepiride, in a single sustained-release formulation. The product is manufactured by USV Pvt Ltd and is supplied in strips containing ten sustained-release tablets. Pack sizes of 60, 120, and 240 tablets are available, providing flexibility for patients with varying treatment durations.

What is Glycomet-GP 3 Tablet

Glycomet-GP 3 Tablet delivers a fixed dose of 850 mg metformin and 3 mg glimepiride per tablet. The sustained-release design allows for a gradual release of the active ingredients over approximately 24 hours, supporting consistent glycemic control when used alongside diet and exercise. This combination addresses both hepatic glucose production and insulin secretion, two central pathways in diabetes pathophysiology.

Uses and Benefits

The primary use of Glycomet-GP 3 Tablet is to improve glycemic control in adults with Type 2 diabetes who have not achieved adequate response to monotherapy. Clinical studies demonstrate that dual therapy with metformin and glimepiride leads to greater reductions in HbA1c compared with either agent alone. Patients may experience improved fasting plasma glucose, post-prandial glucose, and body weight profiles when the medication is integrated into a comprehensive treatment plan.

Benefits include:

• Enhanced glucose lowering potency through complementary mechanisms.
• Convenient dosing with a single daily tablet.
• Sustained-release technology that reduces peak plasma concentrations and minimizes gastrointestinal side effects.

How It Works

Metformin, a biguanide, acts primarily by decreasing hepatic gluconeogenesis and improving peripheral insulin sensitivity. Glimepiride, a sulfonylurea, binds to the Kir6.2 subunit of ATP-sensitive potassium channels on pancreatic beta cells, stimulating insulin release. The synergistic effect of these two agents provides a more comprehensive approach to lowering blood glucose, targeting both insulin resistance and beta-cell dysfunction.

Pharmacokinetic data indicate that the sustained-release formulation results in a slower absorption profile, leading to lower Cmax values and a more stable plasma concentration-time curve. This profile is associated with a reduced risk of hypoglycemia compared with immediate-release glimepiride formulations.

Dosage Guidelines

Typical initiation is one tablet daily with the morning meal, corresponding to 850 mg metformin and 3 mg glimepiride. The dose may be titrated based on therapeutic response and tolerability, with a maximum recommended daily dose of 2 tablets (1700 mg metformin/6 mg glimepiride). Dose adjustments are recommended in patients with renal impairment, hepatic dysfunction, or advanced age, in accordance with prescribing information from the manufacturer and regulatory agencies.

Healthcare providers should monitor renal function (eGFR) prior to initiation and periodically thereafter, as metformin is contraindicated in patients with an eGFR below 30 mL/min/1.73 m2. If renal function declines during therapy, consider dose reduction or discontinuation to mitigate the risk of lactic acidosis.

Side Effects

Like all medications, Glycomet-GP 3 Tablet may cause adverse effects. The most commonly reported side effects include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which are typically mild and transient. Hypoglycemia can occur, especially when used in combination with other insulin secretagogues or insulin, requiring patients to be aware of symptoms such as sweating, tremor, and confusion.

Rare but serious adverse events include lactic acidosis, particularly in patients with significant renal impairment, and hypersensitivity reactions. Patients should discontinue the medication and seek immediate medical attention if they experience unexplained muscle pain, rapid breathing, or severe dizziness.

Warnings and Precautions

Patients should be advised to inform their healthcare provider of any history of renal disease, hepatic disease, heart failure, or prior episodes of lactic acidosis before starting therapy. Concomitant use of certain medications, such as contrast agents for imaging studies, may necessitate temporary discontinuation of metformin to reduce the risk of lactic acidosis.

Special populations, including pregnant or breastfeeding women, should avoid this medication unless explicitly prescribed by a qualified clinician. Regular monitoring of blood glucose and periodic assessment of renal function are essential components of safe prescribing practice.

Frequently Asked Questions

1. Can Glycomet-GP 3 Tablet be taken with food? Yes. The tablet should be taken with the morning meal to reduce gastrointestinal upset.

2. How long does it take to see a reduction in HbA1c? Clinical trials have shown measurable declines in HbA1c after 4 to 6 weeks of consistent therapy, though individual response may vary.

3. Is dose adjustment needed in older adults? Older adults may require lower initial doses and slower titration due to age-related declines in renal function and increased sensitivity to hypoglycemia.

4. What should I do if I miss a dose? If a dose is missed, the patient should take it as soon as remembered unless it is near the time of the next scheduled dose. In that case, the missed dose should be skipped and therapy resumed at the regular schedule.

5. Where can I find more detailed prescribing information? Comprehensive prescribing details are available on the FDA’s drug label database (FDA Drug Labels) and on MedlinePlus (MedlinePlus Diabetes Resource).

Related Products

• Erytop Gel (Clindamycin)
• Okamet 500 Mg (Metformin)
• Angispan TR (Nitroglycerin/Glyceryl Trinitrate)
• Angispan TR 2.5 mg (Nitroglycerin/Glyceryl Trinitrate)
• Angispan TR 6.5 mg (Nitroglycerin/Glyceryl Trinitrate)
• Glimepiride 2 mg (Generic)
• Glimepiride 1 mg (Generic)
• Glycomet-GP 0.5 Forte (Metformin/Glimepiride)
• Glycomet-GP 0.5 Tablet (Metformin/Glimepiride)
• Forxiga 5mg (Dapagliflozin)
• Glycomet-GP 1 Tablet (Metformin/Glimepiride)
• Amaryl M 1mg (Metformin/Glimepiride)